Security
Opus Genetics, Inc. Common Stock · IRD
IRDNASDAQCommon stockCurrentCIK 1228627Updated Oct 28, 2026
Name history
Ocuphire Pharma, Inc. · through Oct 22, 2024REXAHN PHARMACEUTICALS, INC. · through Nov 9, 2020CORPORATE ROAD SHOW DOT COM INC · through Apr 29, 2005FERRARO FRANK · through Apr 29, 2003
IRD price & chart
Loading TradingView…
NASDAQ:IRD on TradingView ↗About the company
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
In the news
Big Pharma Setbacks Create a New Wave of Rebound Plays ↗
Seeking Alpha
Viatris, Opus granted FDA label expansion for Ryzumvi in presbyopia ↗
Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow ↗
Small-cap stocks with strong momentum grades and triple-digit YTD gains ↗
SEC disclosures
Opus Genetics, Inc. files 8-K: Material Event ↗
Recent filings
4 filing
4 filing
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 36,122,000Source | 40,389,000Source | 92,968,000Source | 38,665,000Source | 44,834,000Source | 66,787,000Source | 48,167,000Source | 51,844,000Source | 50,243,000Source | 36,862,000Source | 53,948,000Source | 48,992,000Source |
| Property, Plant and Equipment, NetUSD | 212,000Source | 0Source | 172,000Source | 226,000Source | 0Source | 186,000Source | 239,000Source | 0Source | 199,000Source | 252,000Source | 0Source | 6,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,815,000Source | 36,632,000Source | 88,812,000Source | 32,429,000Source | 41,409,000Source | 59,959,000Source | 41,792,000Source | 47,161,000Source | 45,091,000Source | 30,321,000Source | 50,501,000Source | 42,634,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,916,000Source | 1,857,000Source | 1,041,000Source | 3,399,000Source | 1,358,000Source | 1,731,000Source | 3,080,000Source | 1,924,000Source | 1,995,000Source | 3,563,000Source | 926,000Source | 1,298,000Source |
| Assets, CurrentUSD | 35,910,000Source | 40,389,000Source | 92,696,000Source | 38,439,000Source | 44,834,000Source | 66,601,000Source | 47,928,000Source | 51,844,000Source | 50,044,000Source | 36,610,000Source | 53,948,000Source | 48,986,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 815,000Source | 429,000Source | 2,428,000Source | 1,433,000Source | 1,114,000Source | 3,927,000Source | 1,380,000Source | 1,560,000Source | 1,788,000Source | 515,000Source | 1,099,000Source | 1,453,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 30,155,000Source | 6,089,000Source | 105,954,000Source | 21,192,000Source | 4,198,000Source | 87,887,000Source | 24,251,000Source | 5,787,000Source | 34,895,000Source | 11,295,000Source | 4,042,000Source | 2,753,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 3,000Source | 8,000Source | 6,000Source | 3,000Source | 7,000Source | 5,000Source | 3,000Source | 7,000Source | 3,000Source | 2,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 178,027,000Source | 138,160,000Source | 249,228,000Source | 172,079,000Source | 136,970,000Source | 208,281,000Source | 152,260,000Source | 134,626,000Source | 203,930,000Source | 145,719,000Source | 131,370,000Source | 117,717,000Source |
| Retained Earnings (Accumulated Deficit)USD | -172,066,000Source | -103,863,000Source | -262,222,000Source | -154,612,000Source | -96,337,000Source | -254,124,000Source | -147,192,000Source | -88,572,000Source | -188,589,000Source | -138,998,000Source | -81,466,000Source | -71,480,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,967,000Source | 34,300,000Source | -12,986,000Source | 17,473,000Source | 40,636,000Source | -45,836,000Source | 5,073,000Source | 46,057,000Source | 15,348,000Source | 6,724,000Source | 49,906,000Source | 46,239,000Source |
| Liabilities and EquityUSD | 36,122,000Source | 40,389,000Source | 92,968,000Source | 38,665,000Source | 44,834,000Source | 66,787,000Source | 48,167,000Source | 51,844,000Source | 50,243,000Source | 36,862,000Source | 53,948,000Source | 48,992,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 29,087,000Source | 6,089,000Source | 7,605,000Source | 20,192,000Source | 4,198,000Source | 9,340,000Source | 24,251,000Source | 5,787,000Source | 7,781,000Source | 11,295,000Source | 4,042,000Source | 2,753,000Source |
| Accounts Payable, CurrentUSD | 2,395,000Source | 844,000Source | 1,881,000Source | 1,465,000Source | 634,000Source | 4,422,000Source | 2,430,000Source | 2,064,000Source | 3,293,000Source | 3,148,000Source | 2,153,000Source | 1,069,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 5,171,000Source | — | — | 3,490,000Source | — | — | 3,649,000Source | 4,488,000Source | 8,145,000Source | 1,815,000Source | 1,684,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 1,068,000Source | — | — | 1,000,000Source | — | 1,198,000Source | — | — | 1,129,000Source | — | — | — |
| Short-term InvestmentsUSD | 0Source | 3,000Source | — | 0Source | 5,000Source | — | 1,000Source | 5,000Source | 0Source | 2,000Source | 15,000Source | 49,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,464,000Source | 913,000Source | 3,399,000Source | 3,362,000Source | 3,510,000Source | 1,807,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -264,000Source | -483,000Source | -1,568,000Source | 2,637,000Source | -372,000Source | 1,298,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,155,000Source | -718,000Source | 7,000Source | 220,000Source | 1,082,000Source | -515,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,727,000Source | -8,994,000Source | -35,253,000Source | -25,576,000Source | -1,112,000Source | 14,314,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 1,210,000Source | 0Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 27,595,000Source | 20,465,000Source | 50,023,000Source | 4,186,000Source | 8,979,000Source | 3,786,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 30,815,000Source | 36,632,000Source | 88,912,000Source | 32,429,000Source | 59,959,000Source | 41,792,000Source | 45,091,000Source | 30,321,000Source | 50,501,000Source | 42,634,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 9,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 344,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 816,000Source | 776,000Source | 1,407,000Source | 896,000Source | 1,464,000Source | 913,000Source | 3,399,000Source | 3,362,000Source | 3,510,000Source | 1,807,000Source |
| DepreciationUSD | — | — | — | — | — | — | 13,000Source | 13,000Source | 53,000Source | 10,000Source | 6,000Source | 4,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | -9,525,000Source | 0Source | — | — | -51,364,000Source | 2,805,000Source | -11,515,000Source | 72,000Source | 80,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 4,981,000Source | 2,894,000Source | 6,028,000Source | 5,766,000Source | 5,944,000Source | 6,346,000Source | 21,983,000Source | 18,215,000Source | 11,959,000Source | 7,269,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 12,000Source | 315,000Source |
| InterestExpenseNonoperatingUSD | — | — | 68,000Source | 0Source | — | — | 69,000Source | 0Source | 129,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,454,000Source | -7,526,000Source | -8,098,000Source | -7,420,000Source | -65,535,000Source | -8,194,000Source | -49,591,000Source | -57,532,000Source | -9,986,000Source | 17,888,000Source |
| Operating ExpensesUSD | — | — | 11,390,000Source | 11,876,000Source | 17,235,000Source | 11,788,000Source | 16,521,000Source | 14,299,000Source | 52,795,000Source | 73,066,000Source | 29,612,000Source | 21,624,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 450,000Source | 483,000Source | 1,739,000Source | 534,000Source | 844,000Source | 302,000Source | 1,989,000Source | 4,470,000Source | 1,837,000Source | -14,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 2,250,000Source | 409,000Source | 5,805,000Source | 4,497,000Source | 9,227,000Source | 4,428,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 738,000Source | 5,000Source | 352,000Source | 0Source | 30,000Source | 27,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | 0Source | -1,000Source | -2,000Source | -13,000Source | -34,000Source | -170,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,079,000Source | 3,867,000Source | 755,000Source | 2,882,000Source | 2,157,000Source | 4,370,000Source | 14,196,000Source | 10,992,000Source | 19,049,000Source | 39,850,000Source |
| Operating Income (Loss)USD | — | — | -8,311,000Source | -8,009,000Source | -16,480,000Source | -8,906,000Source | -14,364,000Source | -9,929,000Source | -38,599,000Source | -62,074,000Source | -10,563,000Source | 18,226,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 450,000Source | 483,000Source | 1,739,000Source | 534,000Source | 844,000Source | 302,000Source | 1,989,000Source | 4,470,000Source | 1,837,000Source | -14,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -17,454,000Source | -7,526,000Source | -8,098,000Source | -7,420,000Source | -65,535,000Source | -8,194,000Source | -49,591,000Source | -57,532,000Source | -9,974,000Source | 18,203,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 12,000Source | 315,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,454,000Source | -7,526,000Source | -8,098,000Source | -7,420,000Source | -65,535,000Source | -8,194,000Source | -49,591,000Source | -57,532,000Source | -9,986,000Source | 17,888,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.25Source | -0.29Source | -0.08Source | -0.12Source | -0.75Source | -0.24Source | -0.8Source | -2.15Source | -0.46Source | 0.9Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.25Source | -0.29Source | -0.14Source | -0.12Source | -0.75Source | -0.24Source | -0.8Source | -2.15Source | -0.46Source | 0.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 70,636,887Source | 26,145,080Source | 95,483,280Source | 63,376,392Source | 86,891,352Source | 33,884,920Source | 62,221,901Source | 26,715,526Source | 21,589,821Source | 19,931,080Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 70,636,887Source | 26,145,080Source | 111,384,011Source | 63,376,392Source | 86,891,352Source | 33,884,920Source | 62,221,901Source | 26,715,526Source | 21,589,821Source | 20,597,212Source |
| Interest Expense (non-operating)USD | — | — | 68,000Source | 0Source | — | — | 69,000Source | 0Source | 129,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 12,000Source | 315,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | -9,525,000Source | 0Source | — | — | -51,364,000Source | 2,805,000Source | -11,515,000Source | 72,000Source | 80,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 4,981,000Source | 2,894,000Source | 6,028,000Source | 5,766,000Source | 5,944,000Source | 6,346,000Source | 21,983,000Source | 18,215,000Source | 11,959,000Source | 7,269,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 9,000Source |
| Operating ExpensesUSD | — | — | 11,390,000Source | 11,876,000Source | 17,235,000Source | 11,788,000Source | 16,521,000Source | 14,299,000Source | 52,795,000Source | 73,066,000Source | 29,612,000Source | 21,624,000Source |
Offerings
Registration 333-298100
Registration 333-296551
Registration 333-294295
Filing attachments
ef20083857_ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company’s Phase 1/2 clinical trial, supporting further clinical development New BEST1 data analyses link retinal structure to visual function, enabling focus on regions most likely to respond to treatment OPGx-LCA5 demonstrated sustained impro…
Read attachment ↗ef20083857_ex99-2.htm · 8-K · 2026-10-15
Exhibit 99.2 Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease George Magrath, MD Retina in Rio 2026 2 BEST1: Group of Inherited Retinal Diseases with a Range of Onset and Slow Rate of Progression and no Approved Treatment Options Overview & Prevalence Mutations in BEST1 have been associated with at least five clinically distinct retinal degenerative diseases, with onset from childhood to adulthood1 Accounts for ~3.5% of all IRDs1 Global prevalence*: ~45,400 patient…
Read attachment ↗ef20081922_ex99-1.htm · 8-K · 2026-09-11
EX-99.1 2 ef20081922_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predic…
Read attachment ↗ef20081753_ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ef20081753_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual function, with structural improvements observed…
Read attachment ↗ef20081753_ex99-2.htm · 8-K · 2026-09-09
EX-99.2 3 ef20081753_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predic…
Read attachment ↗ny20079592x1_ex107.htm · S-3 · 2026-08-07
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Opus Genetics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Re…
Read attachment ↗